What to expect in the Dyne Therapeutics, Inc. interview process

Based on publicly available sources, Dyne Therapeutics is a publicly traded biotechnology company founded in 2017 and headquartered in Waltham, Massachusetts, with an additional office in Cambridge. The company operates in the rare disease space, focusing on nucleic acid therapies targeting muscle and central nervous system (CNS) diseases, with clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), alongside preclinical work in FSHD and Pompe disease.

Financial and organizational data show that Dyne Therapeutics has experienced rapid headcount growth. Public records track its employee count rising from 47 in 2020 to 191 by the end of 2024, and reaching approximately 238 to 265 employees. The company maintains a market capitalization around $3.5B to $3.9B while operating as a clinical-stage entity with $0 to $1M in annual revenue.

Regarding immigration and global talent acquisition, employment-based tracking data indicates active participation in visa sponsorship, including H-1B petitions (such as 6 approved petitions in fiscal year 2025 and 1 filed in fiscal year 2026) alongside certified Labor Condition Applications and green card filings. Its workforce is distributed internationally across eight countries, including the United States, United Kingdom, Switzerland, Netherlands, and Spain. ESG transparency evaluations assign the company an overall UN SDG transparency score of 3.3, reflecting scores across environmental, social, and governance reporting metrics.